Expert Ratings for ANI Pharmaceuticals
Portfolio Pulse from Benzinga Insights
Over the past 3 months, 6 analysts have published their opinion on ANI Pharmaceuticals (NASDAQ:ANIP) stock, all of them being bullish. The average 12-month price target for ANI Pharmaceuticals has increased by 16.31% from the previous average price target of $60.33 to $70.17.
October 19, 2023 | 7:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
ANI Pharmaceuticals has received bullish ratings from all 6 analysts covering the stock. The average 12-month price target has increased by 16.31% to $70.17.
The unanimous bullish sentiment among analysts and the increase in the average 12-month price target suggest a positive outlook for ANI Pharmaceuticals. This could potentially lead to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100